According to Science and Technology Daily, recently, the innovative drug istevir hydrochloride tablets, jointly developed by Westlake University, Xihu Laboratory, and Xihu Pharmaceutical Co., Ltd. were officially approved for marketing by the State Drug Administration with conditions. The drug can be used to treat light and medium novel coronavirus infections in adults. Apsvir is the first original drug approved for marketing in China using artificial intelligence assisted research and development — it only took three and a half years from source discovery to completion of clinical trials. According to rough statistics from the Securities Times and Databao, the A-share market lays out nearly 40 concept stocks in the AI medical business. As of the close of trading on September 4, the total market value of concept stocks was about 1.07 trillion yuan. Eight concept stocks have accumulated a cumulative increase of more than 10% during the year, namely Bepsis, Medi Technology, Lexin Healthcare, Chengdu Pilot, Hongbo Pharmaceutical, Haoyuan Pharmaceutical, Dashi Intelligence, and Dian Diagnosis. In terms of performance data, in the first half of this year, the net profit of a total of 14 AI medical concept stocks increased year-on-year. The net profit growth rate for the first half of the year was higher, such as Dian Diagnosis, Hokuriku Pharmaceutical, Chengdu Pilot, Lexin Healthcare, and Runhe Software. According to data treasure statistics, judging from institutional concerns, a total of 12 AI medical concept stocks received “positive” ratings from 5 or more institutions, such as Mindray Healthcare, Hengrui Pharmaceutical, Air Ophthalmology, Yunnan Baiyao, and Huadong Pharmaceutical.

According to Science and Technology Daily, recently, the innovative drug istevir hydrochloride tablets, jointly developed by Westlake University, Xihu Laboratory, and Xihu Pharmaceutical Co., Ltd. were officially approved for marketing by the State Drug Administration with conditions. The drug can be used to treat light and medium novel coronavirus infections in adults. Apsvir is the first original drug approved for marketing in China using artificial intelligence assisted research and development — it only took three and a half years from source discovery to completion of clinical trials. According to rough statistics from the Securities Times and Databao, the A-share market lays out nearly 40 concept stocks in the AI medical business. As of the close of trading on September 4, the total market value of concept stocks was about 1.07 trillion yuan. Eight concept stocks have accumulated a cumulative increase of more than 10% during the year, namely Bepsis, Medi Technology, Lexin Healthcare, Chengdu Pilot, Hongbo Pharmaceutical, Haoyuan Pharmaceutical, Dashi Intelligence, and Dian Diagnosis. In terms of performance data, in the first half of this year, the net profit of a total of 14 AI medical concept stocks increased year-on-year. The net profit growth rate for the first half of the year was higher, such as Dian Diagnosis, Hokuriku Pharmaceutical, Chengdu Pilot, Lexin Healthcare, and Runhe Software. According to data treasure statistics, judging from institutional concerns, a total of 12 AI medical concept stocks received “positive” ratings from 5 or more institutions, such as Mindray Healthcare, Hengrui Pharmaceutical, Air Ophthalmology, Yunnan Baiyao, and Huadong Pharmaceutical.